Ustekinumab achieved the highest clinical and endoscopic response rates in chronic pouchitis, while tofacitinib was linked to more adverse events.
Twelve fecal metabolites are significantly altered among patients with irritable bowel syndrome compared with healthy control individuals.
Increased colorectal cancer screening rates are significantly associated with declining mortality, though racial and socioeconomic disparities persist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback